Compare BridgeBio Pharma Inc (BBIO) vs Commvault Systems Inc (CVLT) Price & Performance

BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.

Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.

Commvault (CVLT) trades at $148.65, down 1.28% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.28 exceeding the $1.09 estimate, though Q3 2025 missed expectations. Revenue reached $995.62 million in 2025, with a net income margin of 5.97%. However, valuation ratios are elevated, including a P/E of 94.03 and P/B of 821.14, indicating high growth expectations. Recent news highlights multiple class-action lawsuits with a July 17, 2026 deadline, adding legal overhangs.

The outlook for CVLT is mixed, with solid profitability and analyst buy ratings (54.55% consensus) supporting upside to the $155.00 high target, but risks from the lawsuits and rich valuations could pressure the stock. Investors should weigh robust cash flow growth in 2026 against potential legal and competitive headwinds in the data protection sector.